North Dakota Gov. Doug Burgum has handed his final budget blueprint to lawmakers that includes a rosy picture based largely ...

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025LYTENAVA™ is the first and only approved ...

Outlook Therapeutics (OTLK) announced that the National Institute for Health and Care Excellence, NICE, has recommended LYTENAVA, as an option ...

Discover the best CRM for Outlook integration to enhance your productivity. Compare different solutions and explore your ...

Shares of AT&T Inc. T rose sharply during Tuesday's session after the company updated its 2024 guidance, raising the bottom ...

Health care stocks have underperformed in recent months on uncertainty surrounding the incoming Donald Trump administration, but they can often be a solid defensive play in an uncertain economy.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Congruence Therapeutics Inc. to generate novel small-molecule correctors against multiple protein targets in ...

Fintel reports that on December 2, 2024, Chardan Capital downgraded their outlook for Outlook Therapeutics (NasdaqCM:OTLK) from Buy to Neutral. Analyst Price Forecast Suggests 1,865.37% Upside As of ...

In the assessment of 12-month price targets, analysts unveil insights for Voyager Therapeutics, presenting an average target ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for Outlook Therapeutics in a report issued ...

On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...